drugset
drugset / Trial / NCT06423794

BHV-7000 Open-Label Extension Bipolar Mania Study

NCT06423794 ↗

Phase 2 Terminated 94 enrolled Biohaven Therapeutics Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

Timeline

Start
2024-06-24
Primary completion
2025-04-25
Completion
2025-04-25

Outcome

Outcome not reported

Stopped (Business): “Business Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject BHV-7000 Unknown 75 mg —

Indications

bipolar disorder